Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomised clinical trial

PharmacoEconomics

Volumn 15, Issue 5, 1999, Pages 469-480

  Hamilton, Susan H ^a   Revicki, Dennis A ^b   Edgell, Eric T ^a   Genduso, Laura A ^a,c   Tollefson, Gary ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c Medicina Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST UTILITY ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0032899589     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915050-00005     Document Type: Article

References (65)

1. Bland RC, Parker JH, Orn H. Prognosis in schizophrenia: A ten-year follow-up of first admissions. Arch Gen Psychiatry 1976; 33: 949-54
2. McGlashan TH. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988; 14: 515-42
3. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: A comparison with general population suicide mortality. Arch Gen Psychiatry 1978; 35: 153-5
4. Tsuang MT, Woolson RF. Excess mortality in schizophrenia and affective disorders: Do suicides and accidental death solely account for this excess? Arch Gen Psychiatry 1978; 35: 1181-5
5. Bromer EJ, Dew MA, Eaton W. Epidemiology of psychosis with special reference to schizophrenia. In: Tsuang MT, Tohen M, Zahner GEP, editors. Textbook in Psychiatric Epidemiology. New York (NY): John Wiley & Sons, 1996: 283-300
6. Keith SJ, Regier DA, Rae DS. Schizophrenic disorders. In: Robins LN, Regier DA, editors. Psychiatric disorders in America: the epidemiologic catchment area study. New York (NY): Free Press, 1991
7. Rice D, Miller L. The economic burden of schizophrenia. The 6th Biennial Research Conference on Economics in Mental Health; 1992 Sep 21-22; Bethesda (MD), 21-2
8. Rice D, Miller L. The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, editors. Handbook of Mental Health Economics and Health Policy. Vol. 1. New York (NY): John Wiley & Sons, 1996: 321-34
9. Rupp A, Keith SJ. The costs of schizophrenia: Assessing the burden. Psychiatr Clin North Am 1993; 16: 413-23
10. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-29
11. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995; 21: 567-78
12. Hegerty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: A meta-analysis of the outcome literature. Am J Psychiatry 1994; 151: 1409-16
13. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 105-14
14. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19: 287-302
15. Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet 1995; 346: 820-5
16. Kane JM. Schizophrenia. N Engl J Med 1996; 334: 34-9
17. Keith SJ. Pharmacologic advances in the treatment of schizophrenia. N Engl J Med 1997; 337: 851-2
18. Lehman AF. Evaluating outcomes of treatments for persons with psychotic disorders. J Clin Psychiatry 1996; 57 Suppl. 11: 61-7
19. Borison RL. Recent advances in the pharmacotherapy of schizophrenia. Harv Rev Psychiatry 1997; 4: 255-71
20. Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 1997; 22: 256-66
21. Revicki DA. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: Clozapine-related studies. J Clin Psychiatry 1999; 60 Suppl. 1: 7-11
22. Revicki DA, Luce BR, Weschler J, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850-4
23. Meltzer H, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150: 1630-8
24. Frankenburg FR, Zanarini MC, Cole JO, et al. Hospitalization rates among clozapine-treated patients: A prospective cost-benefit analysis. Ann Clin Psychiatry 1992; 4: 247-50
25. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994; 45: 261-4
26. Jonsson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995; 92: 199-201
27. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study. Clin Ther 1993; 15: 917-26
28. Guest JF, Hart WM, Cookson RF, et al. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996; 10: 59-67
29. Frank RG. Clozapine's cost-benefits [letter]. Hosp Community Psychiatry 1991; 42: 92
30. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: A review. J Clin Psychiatry 1994; 55 Suppl. B: 161-5
31. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996; 57 Suppl. 9: 66-76
32. Essock SM, Hargreaves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial. Psychopharmacol Bull 1996; 32 (4): 683-97
33. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 809-15
34. Mahmoud RA, Engelhart LM, Oster G, et al. Risperidone versus conventional antipsychotics: A prospective randomized naturalistic effectiveness trial of outcomes in chronic schizophrenia. 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 8-12; Kamuela (HA)
35. Beasley CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: Results of a double-blind, fixed dose olanzapine trial. Psychopharmacology 1996; 124: 159-67
36. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-23
37. Beasley CM. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Response. Neuropsychopharmacology 1997; 16: 89-90
38. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-65
39. Revicki DA, Genduso L, Hamilton S, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other related psychotic disorders: Quality of life and clinical outcomes of a randomised clinical trial. Qual Life Res. In press
40. Tollefson G. Long-term continuation therapy with olanzapine: New Clinical Drug Evaluation Unit (NCDEU) Program. NCDEU Meeting; 1997 May 27-30; Boca Raton (FL)
41. Dellva MA, Tran P, Tollefson GD, et al. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997; 46: 1571-7
42. Diagnostic and Statistical Manual of Mental Disorders. 3rd Ed. Washington, DC: American Psychiatric Association, 1987
43. Woerner MG, Mannuza S, Kane JM. Anchoring the BPRS: An aid to improved reliability. Psychopharmacol Bull 1988; 24: 112-7
44. Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare (DHEW), 1976. DHEW publication no. (ADM): 76-338
45. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, Inc., 1986
46. Heinrichs DW, Hanlon TE, Carpenter WT. The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388-98
47. International Classification of Diseases, 9th Revision, Clinical Modification. 4th Ed. Los Angeles (CA): Practice Management Information Corporation (PMIC), 1993
48. Finkler S. The distinction between costs and charges. Ann Intern Med 1982; 96: 102-9
49. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 1990; 6: 57-75
50. Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in Health and Medicine. New York (NY): Oxford University Press, 1996
51. Payment for part B medical and other health services. Fed Regist 1994; 59: 235
52. Reed SK, Hennessy KD, Mitchell OS, et al. A mental health capitation program. II: Cost-benefit analysis. Hosp Community Psychiatry 1994; 45: 1097-103
53. Dwyer DS, Mitchell OS, Cole R, et al. Evaluating Mental Health Capitation Treatment: Lessons from Panel Data. Cambridge (MA): National Bureau of Economic Research, 1995
54. US Bureau of Labor Statistics. CPI Detailed Report. Washington, DC: US Bureau of Labor Statistics, Department of Labor, 1995
55. Palmer CS, Revicki DA, Halpern MT, et al. The cost of suicide and suicide attempts in the United States. Clin Neuropharmacol 1995; 18 Suppl. 3: S25-33
56. National Association of Psychiatric Health Systems. Trends in Psychiatric Health Systems: 1995 Annual Survey, Final Report. Washington, DC: National Association of Psychiatric Health Systems, 1995
57. Physicians GenRx. 5th Ed. St. Louis (MO): Mosby-Year Book, 1995
58. Red Book Pharmacy's Fundamental Reference. Montville (NJ): Medical Economics Data Production Company, 1995
59. Glazer W, Ershefsky L. A pharmacoeconomic model of outpatient neuroleptic therapy in 'revolving door' schizophrenic patients. J Clin Psychiatry 1996; 57 (8): 337-45
60. Rutten-Van Molken MPMH, Van Doorslaer EKA, Van Vliet RCJA. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ 1994; 3: 333-45
61. Anderson KH, Mitchell JM. Expenditures on services for persons with acquired immunodeficiency syndrome under a Medicaid home and community-based waiver program: Are selection effects important? Med Care 1997; 35 (5): 425-39
62. Manning WG, Newhouse JP, Duan N, et al. Health insurance and the demand for medical care. Am Econ Rev 1987; 77: 251-77
63. SAS Institute, Inc. SAS/STAT User's Guide. Vols. 1 & 2. 4th Ed. Version 6. Cary (NC): SAS Institute, Inc., 1990
64. Drummond MF, Stoddart GL. Economic analysis and clinical trials. Control Clin Trials 1984; 5: 115-28
65. Obenchain RL, Johnstone BM. Mixed-model imputation of cost data for early discontinuers from a randomized clinical trial. Drug Inf J 1999; 33: 191-209